FOR IMMEDIATE RELEASE: Willis-Ekbom Disease Foundation Reverts to Original Name AUSTIN, Texas, May 1, 2015 – The Willis-Ekbom Disea...

Study sheds light on treatment for Willis-Ekbom disease (restless legs syndrome): Pregabalin (Lyrica) found as effective as FDA-approved pr...

Editor British Medical Journal January 20, 2014 Dear Editor, As interim director of the Willis-Ekbom Disease Foundation and mot...

An article published December 19 in the British Medical Journal questions current practices in WED/RLS diagnosis and treatment. We are ask...

Dear WED/RLS Community, After 12 wonderful years at the Foundation, I have made the difficult decision to retire from my position as Execu...

Thank you to everyone that  participated  in the Give to the Max Day event. We exceeded our goal by $834! Individual Gifts = $10,834 ...

Results from the “Patient Odyssey” Survey OVERVIEW The “Patient Odyssey” survey, conducted by the Willis-Ekbom Disease (WED) Foundation and ...

-- Survey Reveals Significant Long-Term Challenges in RLS/WED Management -- Rochester, MN — Santa Clara, CA — November 13, 2013 —The Willi...

Specialists with expertise managing Willis-Ekbom disease (restless legs syndrome, or WED/RLS) are invited to apply for certification as WED...

Dear Friend, You have an opportunity to help us make even more of a difference for our Foundation.  Have you ever written an online revie...

The Foundation is putting together a Parent Advisory Board to develop and implement a new program (Hearing Children's Voices) to addres...

Rochester, Minn. – [August 1, 2013] – The WED/RLS Quality Care Center Program will establish a network of healthcare providers with expert...

Anticipates Product in Pharmacies in Early June SANTA CLARA, Calif.--( BUSINESS WIRE )-- XenoPort, Inc. (Nasdaq: XNPT) announced today t...

A shortage of Horizant continues to impact the WED/RLS community. A medication approved by the FDA in 2011 to treat WED/RLS symptoms, Horiz...

Flickr Images